key: cord-0780470-5i0qdqrg authors: Campelo Batalha Cox Moore, Daniella; Fernandes Nehab, Marcio; Gonçalves Camacho, Karla; Teixeira Reis, Adriana; de Fátima Junqueira-Marinho, Maria; Marques Abramov, Dimitri; Maria Almeida de Azevedo, Zina; Almeida de Menezes, Livia; dos Santos Salú, Margarida; Eduardo da Silva Figueiredo, Carlos; Elisabeth Lopes Moreira, Maria; Farias Meira de Vasconcelos, Zilton; Amendola Anisio de Carvalho, Flavia; de Rezende de Mello, Livia; Fernandes Correia, Roberta; Clair dos Santos Gomes Junior, Saint title: Low COVID-19 Vaccine Hesitancy in Brazil date: 2021-09-07 journal: Vaccine DOI: 10.1016/j.vaccine.2021.09.013 sha: 6f37015df5acf460debf54e45c2e77449897e923 doc_id: 780470 cord_uid: 5i0qdqrg Background The COVID-19 pandemic has affected the entire world, and the vaccine has emerged as a source of hope for return to normal life. Still, various countries have reported high vaccine hesitancy rates. It is important to know the vaccine hesitancy profile in Brazil to help design adequate communication strategies. Methods A voluntary, anonymous online survey was conducted from January 22 to 29, 2021, including resident Brazilian adults to assess factors related to vaccine hesitancy. Sociodemographic and epidemiological data were analyzed. A bivariate analysis was conducted with the independent variables, with vaccine hesitancy as the outcome variable, and a multivariate logistic model was used to calculated adjusted odds ratios. Results The sample included 173,178 respondents, and vaccine hesitancy was found in 10.5%. The principal factors associated with vaccine hesitancy were the following: assigning importance to the vaccinés efficacy (AOR=16.39), fear of adverse reactions (AOR = 11.23), and assigning importance to the vaccinés country of origin (AOR=3.72). Other risk factors were the following: male gender (AOR=1.62), having children (AOR=1.29), 9 years of schooling or less (AOR=1.31), living in the Central-West region (AOR=1.19), age ≥ 40 years (AOR=1.17), and monthly income < U$788.68 (AOR=1.13). The two vaccines available in Brazil, Covishield and CoronaVac, showed similar confidence, 80.13% and 76.36%, respectively, despite the higher rejection of the latter vaccinés Chinese origin. Interpretation: This online survey confirms the low vaccine hesitancy rate among Brazilians and allowed the identification of a profile that can assist the elaboration of communication strategies to increase vaccine adherence. Funding: National Institute of Womeńs, Childreńs and Adolescentś Health Fernandes Figueira, FIOCRUZ, Rio de Janeiro, Brazil. The COVID-19 pandemic has affected the entire world, and the vaccine has emerged as a source of hope for return to normal life. Still, various countries have reported high vaccine hesitancy rates. It is important to know the vaccine hesitancy profile in Brazil to help design adequate communication strategies. A voluntary, anonymous online survey was conducted from January 22 to 29, 2021, including resident Brazilian adults to assess factors related to vaccine hesitancy. Sociodemographic and epidemiological data were analyzed. A bivariate analysis was conducted with the independent variables, with vaccine hesitancy as the outcome variable, and a multivariate logistic model was used to calculated adjusted odds ratios. The sample included 173,178 respondents, and vaccine hesitancy was found in 10.5%. The principal factors associated with vaccine hesitancy were the following: assigning importance to the vaccine´s efficacy (AOR=16.39), fear of adverse reactions (AOR = 11.23), and assigning importance to the vaccine´s country of origin (AOR=3.72). Other risk factors were the following: male gender (AOR=1.62), having children (AOR=1.29), 9 years of schooling or less (AOR=1.31), living in the Central-West region (AOR=1. 19) , age ≥ 40 years (AOR=1.17), and monthly income < U$788.68 (AOR=1.13). The two vaccines available in Brazil, Covishield and CoronaVac, showed similar confidence, 80.13% and 76.36%, respectively, despite the higher rejection of the latter vaccine´s Chinese origin. This online survey confirms the low vaccine hesitancy rate among Brazilians and allowed the identification of a profile that can assist the elaboration of communication strategies to increase vaccine adherence. Since 2020, the COVID-19 pandemic has caused more than 250 thousand deaths in Brazil(1). The incidence and mortality rates are still high, with numerous cities facing an overload on their healthcare services, healthcare workers´ exhaustion, and shortage of hospital beds and essential inputs (2) . The availability of vaccines for the prevention of COVID-19 in the world and the beginning of vaccination in Brazil in January have raised hope for control of the pandemic. However, despite the benefits of vaccination, vaccine hesitancy has been identified as the cause of resurgence of vaccine-preventable diseases such as measles (3) . Despite the severity of COVID-19, hesitancy with the COVID-19 vaccine has been observed in other countries (4) (5) (6) (7) . In Brazil, despite the alarming number of cases, the intense circulation of fake news in the social media raises concerns with vaccine confidence. Given the lack of effective curative treatments, safe and effective COVID-19 vaccines are critical for a significant reduction in the epidemic curve (5) . Although some studies estimate that immunization of 40-60% of the population is necessary to reach herd immunity (8) , but as the pandemic enters its second year, the challenge of reaching a herd-immunity threshold was looking unlikely because of factors such as vaccine hesitancy, the emergence of new variants and the delayed arrival of vaccinations for children (9) . In this scenario, it is important to understand the profile of vaccine-hesitant To estimate the required sample size, an a priori power analysis was conducted. Based on the total population of Brazilians (n=≈213 million), with 50% prevalence of hesitancy, with 99,9% confidence levels, and a conservative 1% margin of error, a total of 36474 participants were needed for the study (3,233 from North region, 9,860 from northeast region, 15,326 from Southeast, 5,198 from South region and 2,857 from Central West region. The study´s outcome is vaccine hesitancy according to the criteria of the SAGE Working Group on Vaccine Hesitancy, defining hesitancy as delay in acceptance or outright refusal of vaccines (11) . The current study thus defined vaccine-hesitant individuals as those who did not intend to be vaccinated, those who were unsure, and those who would only agree to be vaccinated depending on which vaccine was used. The following independent variables were considered: 1) demographic: gender (male, female, other, or prefer not to answer), age bracket (18- Data were coded and analyzed in the SPSS software. All the variables were analyzed according to their absolute and relative frequencies. Bivariate analysis was performed with vaccine hesitancy as the outcome. This analysis used the chi-square test, and statistical significance of differences was set at p-value < 0.05. A multivariate logistic model was used to calculate adjusted odds ratios with the respective 95% confidence intervals for the set of statistically significant variables in the bivariate analysis. After exclusions (14,096), a total of 173,178 answers were included for analysis. The exclusions were: respondents that do not meet the inclusion criteria because were not Brazilians (1,019) or not residing in Brazil (451), blank forms (1,459) and duplicated records (11, 167) . The great majority of Brazilians who participated in the survey intended to be vaccinated (150,845) or had already been vaccinated against COVID-19 (4,083). Vaccine hesitancy was observed in 10.5% (18, 250) , and of these, 2.5% (4,401) did not intend to be vaccinated, 1.3% (2,274) were unsure, and 6.7% (11, 575) would only agree to be vaccinated depending on the vaccine that was available, as shown in Figure 1 . Vaccine hesitancy was assessed according to sociodemographic, COVID-19related, and vaccine-related variables, as shown in Table 1 A total of 6.7% of participants stated that their decision to vaccinate depended on More than one answer was allowed. Multivariate logistic regression analysis was performed to identify groups with higher and statistically significant odds ratios for predicting vaccine hesitancy. when a vaccine became available in 32,361 adults and showed that 64% intended to vaccinate, 23% were unsure, and 14% did not intend to vaccinate (14) . A study in China has difficulty accepting or understanding data on the pandemic, behaving as science denialists (19) . It is important to address this issue, since vaccine hesitancy in this group was high, at 26%. More than two-thirds of the participants in the study were women (67.1%), which has also been seen other studies (12) (13) (14) (15) . However, vaccine hesitancy was higher in men, unlike findings in other studies (4, 12, 14) . This is relevant in the context of COVID-19, since men show higher risk of severe clinical evolution, indicating that campaigns should also focus on this more vaccine-hesitant gender (20) . Some authors have suggested that this involves a sociocultural issue, where men are more likely to disguise fear and reject preventive practices, explaining this higher vaccine hesitancy rate in men (21, 22) . The vaccine hesitancy rate was inversely related to schooling and income, corroborating other studies (12, 14) . Among respondents that stated being against all the vaccines already in use for other diseases, that is, with an antivax profile, 13.3% were willing to take the COVID- Even with these low vaccine hesitancy rates when compared to other countries, the identification of fear of adverse reactions (11.23 time higher in the vaccine hesitancy group) can help orient awareness-raising campaigns on the vaccines´ safety, further increasing vaccination adherence. Our data also showed that parents present higher vaccine hesitancy (11.9%), which has been reported in other studies (12, 14) . Fear of an adverse reaction to the vaccine that would prevent them from caring for their children has been suggested as a possible cause of this hesitancy. Even among participants who stated being in favor of the traditionally used vaccines, 7.7% showed vaccine hesitancy for the prevention of COVID-19, which may also reflect concern over this vaccine´s safety. Considering that 13,407 participants viewed the vaccine´s efficacy as an important factor in the decision to vaccinate, but that more than double this number The two vaccines were considered the most reliable, ahead of the Pfizer and Moderna vaccines, whose efficacy has been rated higher in clinical trials. The trust in and respect for these vaccines can probably be explained by the fact that these are the vaccines currently supplied to the Brazilian population and the ones produced in partnerships with nationally renowned research institutes, namely FIOCRUZ and the Butantan Institute. Among the study´s limitations, although the survey was answered by persons from all regions of Brazil, the Southeast accounted for 61.8% of the respondents, which may have created a selection bias. Another important limitation was the lower proportion of respondents with low schooling and income, since these strata presented higher vaccine hesitancy. Given that 46.6% of the Brazilian population 25 years or older has nine years of schooling or less, the true vaccine hesitancy rate may be higher than measured in this study (15) . According to this study, Brazilians have high intention to vaccinate to prevent COVID-19, evidencing that access to the vaccine is a bigger problem than vaccine hesitancy in Brazil. In this context, wealthy countries, which represent a small proportion of the world population, have already purchased more than 53% of the available vaccines, and vaccine developers have shown no intention to share the technology, thus drastically curtailing vaccination coverage in poor countries in 2021 (24) . As already discussed, the lack of access to vaccines in low-and middle-income countries, with 75% of the world´s population, seriously challenges global responsibility and equity(25). There are currently two vaccines available in Brazil, CoronaVac (Sinovac) and Covishield (AstraZeneca/Oxford's AZD1222), with low numbers of doses in relation to the Brazilian population, leading to slow immunization, even in the priority groups. The global context notwithstanding, it is not possible to exempt local leaders and government from their responsibility in this short supply of vaccine doses (26) . It is essential to guarantee access to the vaccine and fight vaccine hesitancy, which is comparatively less in Brazil than in other countries, although in absolute terms it is quite relevant because of Brazil´s large population. This study is of particular importance because it was carried out in the first week of the availability of the vaccine for the prevention of covid in the national territory. Some factors have been identified as important in influencing the vaccine hesitancy and can now be tracked over time It is important to focus special attention on population strata with low schooling and income, besides dealing with sociocultural issues related to males, since these groups concentrate higher vaccine hesitancy rates and require adequate communication strategies. Table 2 . Multiple regression analysis for predictors of vaccine hesitancy in study participants. ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence Vaccine confidence and hesitancy in Brazil. Cadernos de Saúde Pública Vaccine hesitancy: the next challenge in the fight against COVID-19 How can a global pandemic affect vaccine hesitancy? Can a COVID-19 vaccine live up to Americans' expectations? A conjoint analysis of how vaccine characteristics influence vaccination intentions Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom Herd immunityestimating the level required to halt the COVID-19 epidemics in affected countries Five reasons why COVID herd immunity is probably impossible Covid-19 Casos e Óbitos Group on Vaccine Hesitancy. Vaccine hesitancy: Definition, scope and determinants. Vaccine. 14 de agosto de COVID-19 Vaccination Hesitancy in the United States: A Rapid National Assessment Acceptance of the COVID-19 vaccine based on the health belief model: A population-based survey in Hong Kong Attitudes towards vaccines and intention to vaccinate against COVID-19: Implications for public health communications. The Lancet Regional Health -Europe Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China Hesitancy in the time of coronavirus: Temporal, spatial, and sociodemographic variations in COVID-19 vaccine hesitancy High Rates of COVID-19 Vaccine Hesitancy and Its Association with Conspiracy Beliefs: A Study in Jordan and Kuwait among Other Arab Countries. Vaccines (Basel). 12 de janeiro de Assessing the Level and Determinants of COVID-19 Vaccine Confidence in Kenya. Vaccines (Basel). 23 de agosto de 2021 Science Denial and COVID Conspiracy Theories: Potential Neurological Mechanisms and Possible Responses Male sex identified by global COVID-19 metaanalysis as a risk factor for death and ITU admission Men and COVID-19: A Biopsychosocial Approach to Understanding Sex Differences in Mortality and Recommendations for Practice and Policy Interventions Homens e masculinidades e o novo coronavírus: compartilhando questões de gênero na primeira fase da pandemia. Ciência & Saúde Coletiva Vaccine Hesitancy and Building Confidence in COVID-19 Vaccination | GOARN Covid-19: Many poor countries will see almost no vaccine next year, aid groups warn The people's vaccine: How a covid-19 vaccine will be a test of global accountability and equity Covid-19: Social murder, they wrote-elected, unaccountable, and unrepentant 9%) 127,713 (90.1%) Family income (monthly) None ≤ $197.17 $197 8%) 2,828 (9.9%) How important is the vaccine for someone who has already had COVID-19? Not important Not very important I don´t know Important Very important Has a family member died or been admitted to ICU for COVID-19? Yes No Importance of efficacy in decision to vaccinate No Yes I don´t understand efficacy data Indifferent Is the vaccine´s country of origin important in the decision to vaccinate? Yes No